Med Alliance Announces Strategic Agreement With Kaneka


January 2, 2018—Med Alliance, a Switzerland-based medical technology company, announced a strategic agreement with Kaneka Corporation, a Japan-based provider of percutaneous transluminal coronary angioplasty (PTCA) balloons. The agreement involves technical collaboration, product licensing, manufacturing, and distribution for the Med Alliance drug-coated balloon (DCB) in Japan for the treatment of coronary arteries.

The strategic agreement gives Kaneka the distribution rights for the Med Alliance DCB in Japan. Med Alliance will receive the PTCA balloons from Kaneka, coat them with its microreservoir technology, then return them to Kaneka for commercialization.

According to the company, the Med Alliance technology includes microreservoirs made from biodegradable polymer intermixed with the antirestenotic drug sirolimus. The microreservoirs provide controlled and sustained release of sirolimus. Med Alliance’s cellular adhesive technology enables the microreservoirs to be coated onto Kaneka’s PTCA balloon.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.